Cancer as a potential sequela of COVID-19 — should we modify 3D cell culture models accordingly?
-
Published:2023-11-30
Issue:3
Volume:68
Page:
-
ISSN:2587-5779
-
Container-title:Biological Communications
-
language:
-
Short-container-title:BioComm
Author:
Petersen ElenaORCID, Chudakova DariaORCID, Erdyneeva DaianaORCID, Zorigt DulamsurenORCID, Shabalina EvgeniyaORCID, Karalkin PavelORCID, Reshetov Igor
Abstract
COVID-19 pandemic was caused by SARS-CoV-2, a novel virus from the family Coronaviridae, firstly identified in Wuhan, China in 2019. COVID-19 remains one of the main challenges of healthcare, given growing numbers of people with COVID-19 in anamnesis, and given the long-lasting consequences and complications of this disease. Cancer is one of the most common diseases in the world, thus a big part of the population is affected by both COVID-19 and cancer. In this succinct review we refer to several recent works expressing a view that COVID-19 might be oncogenic, and describe molecular mechanisms of such phenomena. Next, we describe several tumorigenic changes in the tissue microenvironment as COVID-19 sequelae, which can potentially affect cancer pathogenesis and response of a tumor to therapy. 3D cell culture models are a “golden standard” of in vitro studies in translational oncology. To the best of our knowledge, 3D cell culture systems to study tumor behavior in the tissue microenvironment affected by COVID-19 have not been developed yet. We propose several actionable steps which can be taken to modify existing 3D cell culture models accordingly, to address the needs of translational oncology in the COVID-19 post-pandemic times.
Publisher
Saint Petersburg State University
Subject
General Agricultural and Biological Sciences,General Biochemistry, Genetics and Molecular Biology
Reference91 articles.
1. Ahmad, S., Manzoor, S., Siddiqui, S., Mariappan, N., Zafar, I., Ahmad, A., and Ahmad, A. 2021. Epigenetic underpinnings of inflammation: Connecting the dots between pulmonary diseases, lung cancer and COVID-19. Seminars in Cancer Biology 83:384–398. https://doi.org/10.1016/j.semcancer.2021.01.003 2. Allen, C. N., Santerre, M., Arjona, S. P., Ghaleb, L. J., Herzi, M., Llewellyn, M. D., Shcherbik, N., and Sawaya, B. E. 2022. SARS-CoV-2 Causes Lung Inflammation through Metabolic Reprogramming and RAGE. Viruses 14(5):983. https://doi.org/10.3390/v14050983 3. Amin, B. J. H., Kakamad, F. H., Ahmed, G. S., Ahmed, S. F., Abdulla, B. A., Mikael, T. M., Salih, R. Q., Salh, A. M., and Hussein, D. A. 2022. Post COVID-19 pulmonary fibrosis; a meta- analysis study. Annals of Medicine and Surgery:103590. https://doi.org/10.1016/j.amsu.2022.1035904. Angioni, R., Bonfanti, M., Caporale, N., Sánchez-Rodríguez, R., Munari, F., Savino, A., Buratto, D., Pagani, I., Bertoldi, N., and Zanon, C. 2022. RAGE engagement by SARS-CoV-2 enables monocyte infection and underlies COVID-19 severity. bioRxiv. https://doi.org/10.1101/2022.05.22.4926935. Augustine, R., Aqel, A. H., Kalva, S. N., Joshy, K., Nayeem, A., and Hasan, A. 2021. Bioengineered microfluidic bloodbrain barrier models in oncology research. Translational Oncology 14(7):101087. https://doi.org/10.1016/j.tranon.2021.101087
|
|